Phase 2 trials of salvage regimens incorporating BV and PD-1 mAbs
| Regimen . | n . | Primary refractory (n [%]) . | ORR . | CRR . | Percentage proceeding to ASCT . | 2-y PFS (%) . |
|---|---|---|---|---|---|---|
| BV → augmented ICE18 | 45 | 25 (56) | Not reported | 27% with BV alone; 76% pre-ASCT. | 98 | 80 (2-y EFS) |
| BV → salvage chemotherapy19 | 57 | 24 (65) | 75% (42/56) with BV alone; 88% (24/28) post-BV chemotherapy. | 43% with BV alone; 68% pre-ASCT. | 88 | 67 |
| BV + bendamustine20 | 55 | 28 (51) | 93% | 74% | 73* | 63 |
| BV + ESHAP21 | 66 | 40 (61) | 91% | 70% | 91 | 71 (2.5-y PFS) |
| BV + nivolumab23 | 62 | 28 (45) | 82% | 61% | 87 | 68 |
| Regimen . | n . | Primary refractory (n [%]) . | ORR . | CRR . | Percentage proceeding to ASCT . | 2-y PFS (%) . |
|---|---|---|---|---|---|---|
| BV → augmented ICE18 | 45 | 25 (56) | Not reported | 27% with BV alone; 76% pre-ASCT. | 98 | 80 (2-y EFS) |
| BV → salvage chemotherapy19 | 57 | 24 (65) | 75% (42/56) with BV alone; 88% (24/28) post-BV chemotherapy. | 43% with BV alone; 68% pre-ASCT. | 88 | 67 |
| BV + bendamustine20 | 55 | 28 (51) | 93% | 74% | 73* | 63 |
| BV + ESHAP21 | 66 | 40 (61) | 91% | 70% | 91 | 71 (2.5-y PFS) |
| BV + nivolumab23 | 62 | 28 (45) | 82% | 61% | 87 | 68 |
EFS, event-free survival.
ASCT was optional.